Skip to main content

AAV-μDys gene therapy to target respiratory deficits in the mdx mouse model of Duchenne Muscular Dystrophy

Conferences
Biswas, D; Hernández Rodríguez, M; El Abiad, S; Fiflis, D; Elmahalawy, A; Balle, E; Mautner, G; Asokan, A; ElMallah, M
Published in: Physiology
May 2026

Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder caused by the absence of functional dystrophin, leading to progressive muscle degeneration, respiratory insufficiency, and ultimately cardiorespiratory failure. Adeno-associated viral (AAV) gene therapy carrying microdystrophin (μDys) was recently FDA approval for DMD, but its impact on respiratory function remains unclear. The goal of this study is to evaluate the therapeutic potential of AAV-cc47, an engineered AAV9-based capsid with enhanced cross-species transduction efficiency, delivering μDys in the mdx mouse model of DMD. The mice received systemic administration of AAV-cc47-μDys at 2mo of age and were assessed bi-monthly for respiratory function using whole-body plethysmography under normoxic (FiO : 0.21; N balance) and hypoxic–hypercapnic (FiCO : 0.07, FiO : 0.10; N balance) conditions, followed by terminal pulmonary mechanics evaluation via forced oscillation. Postmortem analyses were performed at 4mo and 12mo to assess short- and long-term treatment effects. The earlier time point showed no significant differences with therapy, however assessment at 12mo showed partial but significant enhancements in minute ventilation, peak inspiratory and expiratory flow along with overall pulmonary mechanics. Postmortem analysis showed ubiquitous distribution of vector genomes throughout the body, and an increase of dystrophin expression and decreased inflammation in the diaphragm of AAV-cc47-μDys-treated mdx mice. AAV-cc47-μDys treatment slightly improves respiratory function and muscle integrity but does not result in complete correction of DMD pathology. Funding: NHLBI R01HL171282 (MKE) This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Physiology

DOI

EISSN

1548-9221

ISSN

1548-9213

Publication Date

May 2026

Volume

41

Issue

S1

Publisher

American Physiological Society

Related Subject Headings

  • Physiology
  • Biochemistry & Molecular Biology
  • 3208 Medical physiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Biswas, D., Hernández Rodríguez, M., El Abiad, S., Fiflis, D., Elmahalawy, A., Balle, E., … ElMallah, M. (2026). AAV-μDys gene therapy to target respiratory deficits in the mdx mouse model of Duchenne Muscular Dystrophy. In Physiology (Vol. 41). American Physiological Society. https://doi.org/10.1152/physiol.2026.41.s1.2300693
Biswas, Debolina, Maran Hernández Rodríguez, Sara El Abiad, David Fiflis, Amr Elmahalawy, Elle Balle, Gabriela Mautner, Aravind Asokan, and Mai ElMallah. “AAV-μDys gene therapy to target respiratory deficits in the mdx mouse model of Duchenne Muscular Dystrophy.” In Physiology, Vol. 41. American Physiological Society, 2026. https://doi.org/10.1152/physiol.2026.41.s1.2300693.
Biswas D, Hernández Rodríguez M, El Abiad S, Fiflis D, Elmahalawy A, Balle E, et al. AAV-μDys gene therapy to target respiratory deficits in the mdx mouse model of Duchenne Muscular Dystrophy. In: Physiology. American Physiological Society; 2026.
Biswas, Debolina, et al. “AAV-μDys gene therapy to target respiratory deficits in the mdx mouse model of Duchenne Muscular Dystrophy.” Physiology, vol. 41, no. S1, American Physiological Society, 2026. Crossref, doi:10.1152/physiol.2026.41.s1.2300693.
Biswas D, Hernández Rodríguez M, El Abiad S, Fiflis D, Elmahalawy A, Balle E, Mautner G, Asokan A, ElMallah M. AAV-μDys gene therapy to target respiratory deficits in the mdx mouse model of Duchenne Muscular Dystrophy. Physiology. American Physiological Society; 2026.

Published In

Physiology

DOI

EISSN

1548-9221

ISSN

1548-9213

Publication Date

May 2026

Volume

41

Issue

S1

Publisher

American Physiological Society

Related Subject Headings

  • Physiology
  • Biochemistry & Molecular Biology
  • 3208 Medical physiology